Daniel Zimpfer
Overview
Explore the profile of Daniel Zimpfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
298
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Osipenko K, Zimpfer D, Anwar M, Mahr S, Werner P
Eur Heart J Case Rep
. 2025 Mar;
9(3):ytaf082.
PMID: 40046967
Background: Superior vena cava (SVC) aneurysms are rare vascular anomalies, with <80 cases reported worldwide. Large aneurysms carry a risk of rupture and thrombosis, eventually necessitating surgical intervention. Case Summary:...
2.
Andreeva A, Werner P, Zimpfer D, Andreas M
Eur J Cardiothorac Surg
. 2025 Mar;
67(3).
PMID: 40036576
No abstract available.
3.
Baumer U, Kazem N, Hammer A, Hofer F, Steinacher E, Koller L, et al.
J Pers Med
. 2025 Feb;
15(2).
PMID: 39997324
In the era of personalized medicine, tools for risk stratification after cardiovascular interventions are crucial to reduce mortality and morbidity, especially in the aging population. Biomarker-based approaches, in particular, have...
4.
Veen K, Ahmed M, Stark C, Botta L, Anastasiadis K, Bernhardt A, et al.
Eur J Cardiothorac Surg
. 2025 Jan;
67(2).
PMID: 39874447
Objectives: This 4th report aimed to provide insights into patient characteristics, outcomes and standardized outcome ratios of patients implanted with durable Mechanical Circulatory Support across participating centres in the European...
5.
Gustafsson F, Uriel N, Netuka I, Katz J, Pagani F, Connors J, et al.
JAMA Cardiol
. 2025 Jan;
10(3):235-242.
PMID: 39774588
Importance: The Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) study demonstrated that aspirin may be safely eliminated from the antithrombotic regimen after...
6.
Al Asadi H, Abart T, Schwarz C, Moayedifar R, Schaefer A, Marko C, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685693
: Patients with a HeartMate 3 (HM3) left ventricular assist device (LVAD) typically receive anticoagulation and antiplatelet therapy. The HM3 has shown a marked reduction in hemocompatibility-related adverse events (HRAEs)...
7.
Gemelli M, Ronco D, Di Mauro M, Meani P, Kowalewski M, Schwartz G, et al.
Interdiscip Cardiovasc Thorac Surg
. 2024 Dec;
40(1).
PMID: 39673774
Objectives: Post-infarct ventricular septal defect is a rare but devastating complication. Delayed treatment offers better outcomes than emergency surgery, but when acute cardiogenic shock or unstable haemodynamics occur, temporary mechanical...
8.
Gliozzi G, Nersesian G, Gallone G, Schoenrath F, Netuka I, Zimpfer D, et al.
Artif Organs
. 2024 Dec;
PMID: 39655652
Introduction: Left ventricular assist device (LVAD) therapy may lead to an aortic regurgitation, limiting left ventricular unloading and causing adverse events. Whether concomitant aortic valve replacement may improve outcomes in...
9.
Lewin D, Rojas S, Billion M, Meyer A, Netuka I, Kooij J, et al.
JTCVS Open
. 2024 Nov;
21:168-179.
PMID: 39534325
Background: Circulatory support with a catheter-based microaxial flow pump (mAFP) plays a major role in the treatment of severe cardiogenic shock. In most patients who fail to recover while on...
10.
Mutschlechner D, Tscharre M, Wittmann F, Kitzmantl D, Schloglhofer T, Wadowski P, et al.
Res Pract Thromb Haemost
. 2024 Oct;
8(6):102564.
PMID: 39391561
Background: Patients with left ventricular assist devices (LVADs) are treated with a potent antithrombotic regimen to prevent pump thrombosis and thromboembolism. High on-treatment residual platelet reactivity (HRPR) is associated with...